Tampico

Researchers are evaluating additional dosing options of dulaglutide in children and adolescents aged 10 to less than 18 years with Type 2 Diabetes. This phase 3, open-label, multicenter study aims to assess the safety, tolerability, how the drug moves through the body, and effectiveness of dulaglutide at doses of 3.0 mg and 4.5 mg in this pediatric population. Participants have Type 2 Diabetes managed with diet, exercise, metformin, and/or basal insulin. Participants will receive dulaglutide administered subcutaneously at either 3.0 mg or 4.5 mg doses. The study is a single-arm design without a placebo or comparative drug group. The treatment period and follow-up last about 8 months. The study monitors participants throughout this time to evaluate the effects and safety of the dosing options. During the study, researchers will regularly assess participants for any serious adverse events related to the study drug from baseline through week 26. Participants will be monitored for safety, tolerability, and drug levels in the body. The main outcome measure is the number of participants experiencing one or more serious adverse events related to dulaglutide. Overall participation in the study lasts approximately 8 months, including screening and treatment.

Researchers are evaluating maridebart cafraglutide, a drug given as an addition to standard care, to see if it reduces heart-related problems and deaths better than a placebo in people with atherosclerotic cardiovascular disease who are overweight or obese. This phase 3 study focuses on cardiovascular events such as heart attacks, strokes, and deaths related to heart conditions, aiming to improve outcomes in this high-risk population. Participants will receive either maridebart cafraglutide or a placebo, both administered by injection under the skin. The study compares these two groups over a period of up to approximately 35 months, monitoring heart-related health events to assess the drug's impact. The placebo group will receive injections that look identical but contain no active drug, ensuring a double-blind study design. During the study, participants will be regularly evaluated for major cardiovascular events, including heart attack, stroke, heart failure, and death. Researchers will track the time until these events occur to measure the drug's effectiveness. Safety and health will be closely monitored throughout the study period, and participants will be followed for up to nearly three years to gather comprehensive data on cardiovascular outcomes and overall survival.

Researchers are investigating the effectiveness, safety, and tolerability of iptacopan (LNP023) alongside standard care in adults with active lupus nephritis Class III-IV, with or without Class V. This Phase 2 trial aims to assess how well iptacopan works in this condition by comparing it with placebo combined with standard treatments. The study is carefully designed to explore different doses and their impact on kidney health in participants with biopsy-confirmed active lupus nephritis. Participants receive either iptacopan or placebo along with their usual care, including corticosteroids and immunosuppressive drugs like MMF or MPS, for 52 weeks. The study is divided into two parts, both lasting 52 weeks, during which participants take the assigned medications. The treatment is given in a double-blind manner, meaning neither the participants nor the researchers know who is receiving the active drug or placebo. Throughout the study, researchers monitor kidney function and disease activity, focusing on the proportion of patients achieving complete renal response by week 24 without kidney flares. Participants undergo regular assessments including lab tests and clinical evaluations to track their response and safety. They are followed closely during the 52 weeks of treatment to ensure careful observation of effects and any side effects, supporting an in-depth understanding of iptacopan's role in managing lupus nephritis.